GS 3242
Alternative Names: GS-3242Latest Information Update: 23 Oct 2023
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HIV infections
Most Recent Events
- 03 Aug 2023 Preclinical trials in HIV infections (Combination therapy) in USA (Parenteral), prior to August 2023 (Gilead Sciences pipeline, August 2023)